TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden
- PMID: 38245106
- DOI: 10.1016/S2214-109X(23)00590-9
TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden
Conflict of interest statement
AWS is a WHO employee. This was an invited comment, and written on a personal basis. The opinions shared here are those of the author and do not necessarily reflect those of WHO.
Comment on
-
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Glob Health. 2024 Feb;12(2):e257-e270. doi: 10.1016/S2214-109X(23)00522-3. Lancet Glob Health. 2024. PMID: 38245116 Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous